Related Experiment Video
Updated: Jul 2, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Management of morphologic changes associated with antiretroviral use in HIV-infected patients
David Alain Wohl1, Todd T Brown
1AIDS Clinical Trials Unit, University of North Carolina, Chapel Hill, NC 27599, USA. wohl@med.unc.edu
Abstract:
Morphological changes related to altered distribution of regional adipose tissue are well characterized as a potential complication of antiretroviral treatment regimens that can be physically disfiguring and negatively affect the quality of life. Lipoatrophy and lipohypertrophy often occur independently of one another, and the risk of developing these conditions has been associated with specific antiretroviral medications but can also be influenced by a number of host factors. This review details our current understanding of the etiologies of lipoatrophy and lipohypertrophy, including evidence from recent clinical trials, and describes strategies available to manage these conditions. The potential increase in risk of cardiovascular disease associated with these metabolic disturbances is also discussed.
Related Concept Videos
Retrovirus Life Cycles
Cryptococcal Meningitis
Inhibitors of Virion Maturation and Assembly
Pharmacokinetics in Pediatric Patients: Drug Excretion
Therapeutic Drug Monitoring: Affecting Factors
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
